重庆华森制药股份有限公司 关于公司获得健儿消食口服液药品补充申请批准通 证券代码：002907 证券简称：华森制药 公告编号：2025-073 知书暨成为药品上市许可持有人的公告 一、药品基本信息 （一）健儿消食口服液 | 药 | | 品 | | 名 | 称：健儿消食口服液 | | --- | --- | --- | --- | --- | --- | | 剂 | | | | | 型：合剂 | | 注 | | 册 | | 分 | 类：中药 | | 规 | | | | | 格：每支装 10ml | | 受 | | | 理 | | 号：CYZB2501707 | | 通 | | 知 | 书 | 编 | 号：2025B03991 | | 原 | 药 | 品 | 批 | 准 文 | 号：国药准字 Z41021020 | 申 请 内 容：其他：申请进行药品上市许可持有人主体变更，将本 品上市许可持有人由"河南灵佑药业股份有限公司" 变更为"重庆华森制药股份有限公司"。 审 批 结 论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品此次申请事项符合药品注册的有关要求， 同意按照《药品上市后变更管理办法（试行） ...

Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. is holding an online performance briefing for its 2025 semi-annual results to provide investors with a comprehensive understanding of the company's operational status and development strategy [1]. Group 1: Meeting Details - The online performance briefing is scheduled for September 9, 2025, from 15:00 to 16:00, and will be conducted via the "Roadshow China" platform [1]. - Key company leaders, including the chairman, independent directors, CFO, and board secretary, will attend the briefing, although participation may vary due to special circumstances [2]. Group 2: Investor Participation - Investors can register to participate in the online performance briefing by visiting the "Roadshow China" website [3]. - The company is actively soliciting questions from investors ahead of the briefing, with a submission deadline of September 8, 2025, at 17:00, allowing for a more interactive session [3].

Group 1 - The company, Chongqing Huason Pharmaceutical Co., Ltd., will hold a "2025 Semi-Annual Performance Online Briefing" on September 9, 2025, from 15:00 to 16:00 via the "Roadshow China" platform [1] - Key executives including the chairman, independent directors, CFO, and board secretary will attend the online briefing [1] - Investors can participate by registering on the "Roadshow China" website and are encouraged to submit questions via email by September 8, 2025 [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-072 重庆华森制药股份有限公司 关于举行2025年半年度业绩网上说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 四、公开征集问题 为充分尊重投资者，广泛听取投资者的意见和建议，现就公司2025年半年 度业绩网上说明会提前向投资者公开征集问题，提问通道自发出公告之日起开 放。投资者可于2025年9月8日（星期一）17:00前将相关问题通过电子邮件的形 式发送至公司投资者关系邮箱（ir@pharscin.com）。公司将在2025年半年度业 绩网上说明会上，对投资者普遍关注的问题进行回答。欢迎广大投资者积极参 与。 特此公告 重庆华森制药股份有限公司 一、会议时间、地点 业绩说明会将于2025年9月9日（星期二）15:00～16:00通过网络会议的形 式在"路演中"平台举行。 二、参加人员 届时，公司董事长、独立董事、财务总监、董事会秘书等主要领导将出席 本次业绩网上说明会（如有特殊情况，参与人员会有调整）。 三、投资者参加方式 投资者可登录"路演中"（http://www.roads ...

Core Viewpoint - The company, Chongqing Huason Pharmaceutical Co., Ltd., has announced its 2025 semi-annual profit distribution plan, which includes a cash dividend of RMB 0.35 per 10 shares for all shareholders, totaling approximately RMB 14.62 million [2][5]. Profit Distribution Plan - The profit distribution plan was approved by the board on August 21, 2025, following authorization from the 2024 annual shareholders' meeting held on May 21, 2025 [1][3]. - The total share capital as of June 30, 2025, is 417,596,314 shares, serving as the basis for the cash distribution [2][5]. - The distribution will not involve stock increases or bonus shares, and any undistributed profits will be carried forward to future distributions [2][5]. Taxation Details - The cash dividend of RMB 0.35 per 10 shares is subject to tax, with different rates applied based on the type of shareholder and holding period [5]. - For Hong Kong market investors and certain foreign institutions, the net cash distribution will be RMB 0.315 per 10 shares after tax [5]. Key Dates - The record date for the distribution is set for September 8, 2025, and the ex-dividend date is September 9, 2025 [5]. Distribution Method - Cash dividends will be directly credited to shareholders' accounts through their custodial securities companies on the ex-dividend date [7].

Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has announced its profit distribution plan for the first half of 2025, which includes a cash dividend of RMB 0.35 per 10 shares, totaling approximately RMB 14.62 million, to be distributed to all shareholders [1][2]. Profit Distribution Plan - The profit distribution plan was approved at the fourth board meeting on August 21, 2025, with the total share base being 417,596,314 shares [1][2]. - The cash dividend will be distributed as follows: RMB 0.35 per 10 shares (before tax) for all shareholders, while specific tax rates apply for different categories of investors [2]. Dividend Payment Dates - The record date for the dividend distribution is set for September 8, 2025, and the ex-dividend date is September 9, 2025 [2]. Distribution Recipients - The recipients of the dividend will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [3]. Distribution Method - Cash dividends for A-share shareholders will be directly credited to their accounts through their securities companies on the ex-dividend date [3]. - The company will bear all legal responsibilities if there are any discrepancies in the dividend distribution due to changes in shareholders' accounts during the application period [3]. Reference Documents - The announcement includes references to the resolutions from the 2024 annual general meeting and the second meeting of the fourth board of directors, along with confirmation documents from the China Securities Depository and Clearing Corporation [4].

Core Points - Huason Pharmaceutical announced a cash dividend distribution plan for the first half of 2025, proposing a payment of 0.35 RMB per 10 shares to all shareholders [2] Summary by Category - **Dividend Distribution** - The total share capital of the company is 417,596,314 shares, which serves as the basis for the dividend distribution [2] - The record date for the dividend is set for September 8, 2025, and the ex-dividend date is September 9, 2025 [2]

证券代码：002907 证券简称：华森制药 公告编号：2025-071 重庆华森制药股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 根据 2024 年年度股东大会授权，重庆华森制药股份有限公司（以下简称"公司"） 2025 年半年度权益分派方案已获 2025 年 8 月 21 日召开的第四届董事会第二次会议审 议通过，现将权益分派事宜公告如下： 一、利润分配方案审议情况 1.2025 年 5 月 21 日，公司召开 2024 年年度股东大会审议通过了《关于授权董事 会制定 2025 年中期分红方案的议案》，授权董事会根据股东大会决议在符合利润分 配的条件下制定具体的中期分红方案。2025 年 8 月 21 日，公司召开第四届董事会第 二次会议审议通过了《关于公司〈2025 年半年度利润分配预案〉的议案》，具体内容 详见公司分别于 2025 年 5 月 22 日、2025 年 8 月 22 日刊登在《中国证券报》《上海 证券报》《证券日报》《证券时报》和巨潮资讯网（www.cninfo.com.cn）的《2024 ...

Core Viewpoint - The increasing prevalence of throat diseases due to environmental pollution, lifestyle changes, and an aging population is driving the demand for throat traditional Chinese medicine (TCM), with the market expected to reach 7.4 billion yuan in 2024, reflecting a year-on-year growth of 7.49% [1][9]. Overview - Throat diseases are primarily caused by various factors such as wind-heat invasion and internal heat, leading to symptoms like sore throat and hoarseness. Throat TCM is made from traditional Chinese medicinal ingredients and is used to treat throat-related ailments, characterized by stable efficacy and minimal side effects [1][3]. Development History - The throat medicine industry in China began relatively late, with significant advancements in chronic pharyngitis research in the 1980s leading to the development of throat medications. The market was initially fragmented, but the introduction of products like Guangxi Jinsongzi's throat lozenges in 1995 marked a turning point, establishing a competitive landscape [4][5]. Market Policy - The Chinese government has implemented various policies to support the development of the TCM industry, creating a favorable environment for throat TCM growth. These include measures to enhance TCM regulation and promote innovation [5][6]. Industry Chain - The throat TCM industry consists of an upstream segment focused on medicinal herb cultivation, a midstream segment for manufacturing, and a downstream segment involving sales through medical institutions, pharmacies, and e-commerce platforms. The primary consumer groups include individuals who use their voices frequently and patients with chronic throat conditions [6][7][8]. Current Market Situation - The throat TCM market is experiencing rapid growth, with a projected sales figure of 7.4 billion yuan in 2024. Tablets represent the largest segment at 41.65%, followed by granules and pills [1][9]. Competitive Landscape - The throat TCM market is characterized by high concentration, with the top five companies holding over 50% market share in retail pharmacies. Guangxi Jinsongzi leads with a market share of 16.95% [10][11]. Key Companies - Guangxi Jinsongzi Group is a major player in the throat TCM market, with a projected revenue of 1.185 billion yuan in 2024 and a gross profit margin of 75.46% [12]. - Guilin Sanjin Pharmaceutical Co., Ltd. is another key player, with a projected revenue of 2.194 billion yuan in 2024 and a gross profit margin of 73.41% [12]. Future Trends - The throat TCM industry is expected to focus on improving the quality of raw materials and production processes to meet rising consumer demands for high-quality products. Additionally, there is potential for international market expansion, particularly in Southeast Asia, as awareness and acceptance of TCM grow [13].

金融界消息 截至2025年8月25日收盘，华森制药（002907）报收于18.4元，下跌0.38%，换手率3.33%， 成交量9.99万手，成交金额1.84亿元。 通过天眼查大数据分析，重庆华森制药股份有限公司共对外投资了12家企业，参与招投标项目4258次， 知识产权方面有商标信息204条，专利信息135条，此外企业还拥有行政许可207个。 资金流向方面，今日主力资金净流出1278.91万元，占比成交额6.97%。其中，超大单净流出448.79万 元、占成交额2.45%，大单净流出830.12万元、占成交额4.52%，中单净流出流出80.89万元、占成交额 0.44%，小单净流入1359.80万元、占成交额7.41%。 来源：金融界 华森制药最新一期业绩显示，截至2025中报，公司营业总收入4.42亿元、同比增长5.76%，归属净利润 5395.05万元，同比增长14.27%，扣非净利润4675.48万元，同比增长12.52%，流动比率4.242、速动比率 3.771、资产负债率15.43%。 天眼查商业履历信息显示，重庆华森制药股份有限公司，成立于1996年，位于重庆市，是一家以从事医 药制造业为主的企业 ...